Barclays Maintains Overweight on Legend Biotech, Lowers Price Target to $68

Benzinga · 4d ago
Barclays analyst Etzer Darout maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and lowers the price target from $74 to $68.